Bedrijfsoverzicht
IM Cannabis Corp. is a specialized entity engaged in the breeding, cultivation, and supply of medical cannabis products, operating primarily within the healthcare sector under the classification of drug manufacturers specializing in specialty and generic pharmaceuticals. This positioning within the healthcare industry signifies a focus on providing essential medical treatments to patients rather than recreational consumers, distinguishing its operational model from broader cannabis retailers. The company currently maintains a market capitalization of $2.25M and generates annual revenue of $54.73M, while the specific employee count is listed as N/A in available records. The disparity between the substantial annual revenue of $54.73M and the modest market capitalization of $2.25M indicates that the market values the company significantly lower than its current sales output, suggesting a lack of profitability or significant operational challenges that prevent the stock price from reflecting its revenue generation capabilities.
Financiële gezondheid
The financial performance of the company over the trailing twelve months (TTM) shows a revenue of $54.73M, a net income of $-11,319,000, and an EBITDA of $-4,559,000, highlighting a significant negative gap between top-line sales and bottom-line profitability that reveals a heavy cost structure or substantial operational expenses. This negative net income is further exacerbated by a negative free cash flow of $-431,875, which indicates that the company is consuming cash reserves to fund its operations and growth initiatives rather than generating surplus liquidity for shareholders or debt repayment. Profitability metrics across all three levels are negative, with a gross margin of 17.7% indicating that costs of goods sold consume a significant portion of sales, an operating margin of -31.4% reflecting high overhead or administrative costs relative to revenue, and a profit margin of -20.7% confirming the overall unprofitable state of the business. The balance sheet presents a complex picture with cash holdings of $2.73M against total debt of $16.27M, resulting in a debt-to-equity ratio of N/A, which suggests the company is leveraged and potentially vulnerable to liquidity constraints given the inability to service debt without external financing. Liquidity concerns are further underscored by a current ratio of 0.67, which is below the standard benchmark of 1.0, indicating that the company's current assets are insufficient to cover its current liabilities without raising additional capital. Return on Equity is listed as N/A due to the equity structure, while the return on assets stands at -10.9%, revealing that the management's utilization of asset base is currently generating value destruction rather than positive returns for the organization.
Waarderingsbeoordeling
Traditional valuation metrics for this stock present challenges due to the lack of earnings, with a trailing P/E ratio of N/A and a forward P/E of -0.28, a negative figure that implies the market does not expect immediate earnings recovery or is pricing in a significant restructuring period. The price-to-book ratio is recorded at -0.80, a negative multiple that indicates the market is valuing the company's equity below its book value, often seen in distressed situations or speculative assets where future growth potential is valued over current tangible assets. Alternative valuation metrics such as the price-to-sales ratio of 0.04 and an EV/EBITDA of -3.49 suggest that the company is valued extremely cheaply relative to its sales, though these negative multiples reflect the deep losses rather than a discount on a profitable asset. In terms of trading range, the stock has experienced extreme volatility, with a 52-week high of $7.12 and a 52-week low of $0.29, meaning the current price sits significantly closer to the bottom of this range given the recent market performance relative to the highs. The beta of 2.27 indicates that the stock price is highly volatile, moving with more than twice the magnitude of the broader market, which increases risk for investors sensitive to market swings.
Growth & Income
The company demonstrates robust top-line expansion with a revenue growth rate of 17.6% year-over-year, while earnings growth is listed as N/A due to the absence of positive earnings, creating a scenario where revenue expansion is not yet translating into profit improvement. As a non-dividend payer, the company does not distribute income to shareholders, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which implies that any generated cash is theoretically available for reinvestment into the business or debt reduction rather than distribution. The combination of strong revenue growth of 17.6% against a backdrop of negative earnings and negative free cash flow suggests that the company is likely reinvesting all available resources into scaling operations or managing liquidity rather than returning capital to investors. Overall, the growth and income profile is characterized by significant sales momentum coupled with substantial financial losses and no dividend income, presenting a high-risk, high-growth dynamic typical of early-stage biotech or specialized pharmaceutical companies struggling to achieve commercial viability.